Drug Trial Radar · NCT04712097
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
478
Actual
Start
Oct 27, 2021
Primary completion
Jun 3, 2026
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.
Conditions
- Relapsed or Refractory Follicular Lymphoma
Interventions
MosunetuzumabDrug
Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12
LenalidomideDrug
Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
RituximabDrug
Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
TociluzumabDrug
Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) according to 2014 Lugano Response CriteriaTime frame: From randomization to the first occurrence of disease progression as determined by an independent review committee (IRC) or death from any cause (up to approximately 8.5 years)
Locations
111 sites in 15 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Winship Cancer Institute
Atlanta, Georgia
Fort Wayne Medical Oncology and Hematology, Inc
Fort Wayne, Indiana
Investigative Clinical Research of Indiana, LLC
Noblesville, Indiana
Johns Hopkins Uni
Baltimore, Maryland
University of Michigan Health System
Ann Arbor, Michigan
Cancer & Hematology Center of West Michigan
Grand Rapids, Michigan
Washington University
St Louis, Missouri
NYU Long Island Hospital
Mineola, New York
NYU Langone Ambulatory Care Center
New York, New York
Montefiore Medical Center - Montefiore Medical Park
The Bronx, New York
Montefiore Medical Center
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
Wake Forest Univ Health Svcs
Winston-Salem, North Carolina
Baylor University Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Kadlec Clinic Hematology and Oncology
Kennewick, Washington
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Princess Alexandra Hospital Woolloongabba
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Geelong Hospital
Geelong, Victoria, Australia
Ictrials Pesquisa e Desenvolvimento
Curitiba, Paraná, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Mae de Deus
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Alemao Oswaldo Cruz
São Paulo, São Paulo, Brazil
Peking University First Hospital
Beijing, China
Beijing Cancer Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
The First Hospital of Jilin University
Changchun, China
Cancer Center, Sun Yat-sen University of Medical Sciences
Guangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
The 1st Affiliated Hospital of Nanchang Unversity
Nanchang, China
Jiangsu Province Hospital
Nanjing, China
Fudan University Shanghai Cancer Center
Shanghai, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Zhejiang Cancer Hospital
Zhejiang, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.